[go: up one dir, main page]

DE1618028A1 - Process for the preparation of methylacyloxymethyl ketals from prednisolone derivatives with 3 to 5 carbon atoms in the acyl group - Google Patents

Process for the preparation of methylacyloxymethyl ketals from prednisolone derivatives with 3 to 5 carbon atoms in the acyl group

Info

Publication number
DE1618028A1
DE1618028A1 DE19671618028 DE1618028A DE1618028A1 DE 1618028 A1 DE1618028 A1 DE 1618028A1 DE 19671618028 DE19671618028 DE 19671618028 DE 1618028 A DE1618028 A DE 1618028A DE 1618028 A1 DE1618028 A1 DE 1618028A1
Authority
DE
Germany
Prior art keywords
carbon atoms
ketals
methylacyloxymethyl
acyl group
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19671618028
Other languages
German (de)
Inventor
Claeson Karl Goeran
Frist Henn Dr Sct Techn
Ekenstam Af Dr Phil B Turesson
Froelunda Vaestra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saab Bofors AB
Original Assignee
Bofors AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bofors AB filed Critical Bofors AB
Publication of DE1618028A1 publication Critical patent/DE1618028A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von Methyl acyl oxyinethylke tal en aus Prednisolonderi«* vaten mit 3—5 C-Atomen in der Acylgruppe.The present invention relates to a method for Production of methyl acyl oxyinethylketal en from Prednisolonderi «* vaten with 3-5 carbon atoms in the acyl group.

■■"":" ; - Γ ■ -. -:. ■ ■ j Es ist bekannt, Alkyl acyl oxy alkyl ketale aus Prednisolönderi- ■■ "" : "; - Γ ■ -. - :. ■ ■ j It is known that alkyl acyl oxy alkyl ketals from Prednisolönderi-

'.-■ : ■''-■■'■■ - - · -'■ ■■- '■■-."■"■"■ ν - i'.- ■ : ■''-■■' ■■ - - · - '■ ■■ -' ■■ -. "■" ■ "■ ν - i

vaten herzustellen. Diese Verbindungen zeigen einen guten jto produce fathers. These connections show a good j

antiinflaipmatorischen Effekt, insbesondere, wenn die Acylgruppeanti-inflammatory effect, especially when the acyl group

1-2 C-Atome enthält. Versuche mit anderen Acetalen und Ketälen haben ergeben, daß die Anzahl C-Atome in der Acetal-· und Ketal— gruppe niedrig sein sollte. Methylacyloxymethylketale bekannter Art sind u.a. in dem englischen Patent Nr. 1 020 309und dem belgischen Patent 660 5^9 beschrieben.Contains 1-2 carbon atoms. Try other acetals and ketals have shown that the number of carbon atoms in the acetal · and ketal- group should be low. Methylacyloxymethyl ketals better known Art are, inter alia, in English Patent No. 1 020 309 and the Belgian patent 660 5 ^ 9.

00984A/179300984A / 1793

POSTSCHECK» HAMBURG 1*607 · «ANKi COMMERZIANK A. G., HAMIUKG, OCP^CASSe 30/120» « TBfGHM SfECHTZI?* HAMtUKOPOST CHECK »HAMBURG 1 * 607 ·« ANKi COMMERZIANK A. G., HAMIUKG, OCP ^ CASSe 30/120 »« TBfGHM SfECHTZI? * HAMtUKO

iew. SKCHTZIEtMSNCHmiew. SKCHTZIEtMSNCHm

Eine langwierige Forschungsarbeit hat überraschend und im Gegensatz zu üblichen Erfahrungen mit Acetalen und Ketalen aus Cortisonderivaten erfindungsgemäß ergeben, daß eine höhere Anzahl C-Atome in der Acylgruppe des Ketals einen offenbar verbesserten antiinflammatorischen Effekt in Verhältnis zu dem antiinflammatorischen Effekt gibt, der mit Ketalen nach den erwähnten Patenten erhalten wird. Die Anzahl C-Atome in der Acylgruppe soll dabei mindestens 3 und höchstens 5 sein.A lengthy research has surprisingly and im In contrast to usual experiences with acetals and ketals from cortisone derivatives according to the invention show that a higher Number of carbon atoms in the acyl group of the ketal has an apparently improved anti-inflammatory effect in relation to that gives anti-inflammatory effect, which is obtained with ketals according to the patents mentioned. The number of carbon atoms in the The acyl group should be at least 3 and at most 5.

Die Verbindung nach vorliegender Erfindung hat nachstehende allgemeine Formel:The compound of the present invention has the following general formula:

HOHO

- O - C - R,- O - C - R,

00984V/179300984V / 1793

wobei IL eine Alkylgruppe ist t die wenigstens 3 C-Atome und höchstens 5 C-Atome hat, in der P Fluor bedeutet und X Wasserstoff oder Fluor,where IL is an alkyl group t has at least 3 carbon atoms and at most 5 carbon atoms, in which P denotes fluorine and X denotes hydrogen or fluorine,

Für die Herstellung der Verbindungen, die unter vorstehende -Formel fallen, wird nur ein Beispiel angeführt» da. die übrigen Verbindungen in genau der gleichen Weise hergestellt werden können»
Beispiel 1
Only one example is given for the preparation of the compounds that fall under the above formula »da. the other connections can be made in exactly the same way »
example 1

. 6iiinex^ Suspension von 300 mg Triameinolon in 7,5 ml Dioxan ('getrocknet und neudestilliert) werden 2,5 g Kaproyloxyazeton und 25 wg 75:5^ige Perchlorsäure zugesetzt. Das Rcaktionsgeraisch wird 5 Stunden lang bei 20-30 C_ in Stickgasatmosphäre gerührt. Allmählich wird eine homogene saure Lösung gebildet, die mit 5^o Natriuiübikarbonatlösung auf pH 6,5 neutralMert wird. Die Lösung wird mit Chloroform extrahiert, wonach die Chloroformschicht getrocknet und im Vakuum eingedunstet wird. Das Reaktionsprodukt wird aus ca. 10 ml einer Mischung von Äthyläzetat und Ligroin im Verhältnis i:i urakristallisiert,. Das Triaincinolonkaproyloxyazetonid erhält man mit einer Ausbeute von 82$ und einem Schmelzpunkt von 229 -. 6 iiinex ^ suspension of 300 mg of triameinolone in 7.5 ml of dioxane ('dried and redistilled) 2.5 g of caproyloxyacetone and 25 % of 75: 5% perchloric acid are added. The reaction device is stirred for 5 hours at 20-30 ° C. in a nitrogen gas atmosphere. Gradually a homogeneous acidic solution is formed, which is neutralized to pH 6.5 with 5% sodium bicarbonate solution. The solution is extracted with chloroform, after which the chloroform layer is dried and evaporated in vacuo. The reaction product is uracrystallized from approx. 10 ml of a mixture of ethyl acetate and ligroin in the ratio i: i. The Triaincinolonkaproyloxyazetonid is obtained with a yield of $ 82 and a melting point of 229 -

Aus nachstehender Tabelle gehen die Schmelzpunkte der Verbindungen hervor, die unter die vorhergehende allgemeine Formel fallen.The following table shows the melting points of the Connections emerge under the previous general Fall formula.

-3 --3 -

009844/1793009844/1793

Tabelle 1Table 1

Corticosteroidderivate nach R. X SclinieΙζχ)unkt vorstehender Formel CCorticosteroid derivatives according to R. X SclinieΙζχ) item formula C above

Triamciholonbutyroyloxyazetonid Triamcinolonvaleroyloxyazetonid TriamcinolonkaproyloxyazetonidTriamciholonbutyroyloxyazetonide Triamcinolone valeroyloxyazetonide triamcinolone caproyloxyazetonide

Triameinolori-3,3,dimethylbutyroyloxyazetonid Triameinolori-3,3, dimethylbutyroyloxyazetonide

FluocinolonvaleroyloxyazetonidFluocinolone valeroyloxyacetonide

C3Ii7 C 3 Ii 7 IIII 218218 - 220- 220 IIII 210210 - 215- 215 C5nil C 5 n il IIII 229 -229 - 230230 C5Ii11 C 5 Ii 11 IIII 207 -207 - 209209 FlFl 108 -108 - 110110

Der antiinflammatorische Effekt bei den Substanzen der Tabelle 1 ist mit Triamcinolgnacetyloxyaze$iid nach vorstehend genannten Patenten durch den Granulomtest, vgl. Experientia 6, 1950, Seiten 469 — 471, an adrenalektomisierten Mäusen, d.h. Mäusen mit wegoperierten Nebennieren, verglichen worden. Dieses ist an zwei Gruppen von Versuchstieren durchgeführt worden. Der einen Tiergruppe ist subkutan eines der Corticosteroide nach Tabelle 1 zugeführt worden, während die andere Gruppe zur Kontrolle diente. Danach wurden die Gewichtszunahmen der verwendeten "cott.onpellets-" bei den Tieren, die Corticosteroid erhalten haben, mit den Tieren verglichen, die keine Behandlung mit Corticosteroid erhalten haben. Die Ergebnisse .in den genannten Versuchen werden in nachstehender Tabelle zusammengefaßt:The anti-inflammatory effect of the substances in Table 1 is with Triamcinolgnacetyloxyaze $ iid according to the above Patents by the granuloma test, see Experientia 6, 1950, pp 469-471, on adrenalectomized mice, i.e. mice with removed adrenal glands. This has been carried out on two groups of test animals. The one In the animal group, one of the corticosteroids according to Table 1 was administered subcutaneously, while the other group served as controls. Thereafter, the weight increases of the "cott.onpellets" used in the animals that received corticosteroid with the Compared animals not receiving corticosteroid treatment. The results in the experiments mentioned will be summarized in the following table:

BAD ORIGINAL 0 9 8 4 4/1793BAD ORIGINAL 0 9 8 4 4/1793

TabelleTabel

Nr..No.. CorticosteroidCorticosteroid Tages-
dosis
in mg
Daytime
dose
in mg
AnasahlAnasahl
Tiereanimals
Granulom gewichtGranuloma weight
% des Granulomge- % of the granuloma
wichtes der Verweight of ver
suchstiere.search bulls.
11 TriamcinolonaeetyloxyacetonldTriamcinolonaeetyloxyacetonld IQIQ 4848 6969 22 TriamcinolonbutyroyloxyacetonidTriamcinolone butyroyloxyacetonide 1010 88th 6767 33 Triamc inolonvaleroyloxyacetonidTriamc inolone valeroyloxyacetonide 1010 •8•8th 5Q5Q 44th TriamcinolonkaproyloxyacetonidTriamcinolone caproyloxyacetonide 1010 88th 64 ,64, 55 Triameinolon*}* 3-dime tylbutyroyl-
Qxyacetonid "
Triameinolone *} * 3-dimethylbutyroyl-
Qxyacetonide "
1010
66th FluocinolonvaleroyloxyacetonidFluocinolone valeroyloxyacetonide 1010 .8.8th 6262 77th Triame iholon.acetyloxyace tonidTriame iholon.acetyloxyace tonid 3,33.3 3636 8585 88th TriamcinolonbutyroyloxyacetonidTriamcinolone butyroyloxyacetonide 3,33.3 aa 8787 99 TriamcinolonvaleroyloxyacetonidTriamcinolone valeroyloxyacetonide 3,33.3 2424 ;:- 73 ';.; : - 73 ';. 1010 Triamc inolonkaproyloxyacetonidTriamc inolonkaproyloxyacetonid 3,33.3 1616 8282 1111th Triamcinolon-^^-ciinietylbutyroyl-
oxyacetonid
Triamcinolone - ^^ - ciinietylbutyroyl-
oxyacetonide
3,33.3 88th 9999
1212th FluocinononvaleroyloxyacetonidFluocinonone valeroyloxyacetonide 3,33.3 1616 ; 75; 75

Aus dem vorstehenden geht klar und deutlich hervor, dass die Valeroyloxyacetonide im Verhältnis zu den übrigen Verblndungpri einen nachweisbarbesseren antlinflammatorischenEffekt haben<.From the foregoing it is clear that the Valeroyloxyacetonide in relation to the other compound products have a demonstrably better anti-inflammatory effect <.

Claims (4)

PatentansprücheClaims Verfahren zur Herstellung von Verbindungen mit der Formel:Process for making compounds with the formula: 21 CH2-OH21 CH 2 -OH HOHO in der R, eine Alkylgruppe ist, und in der P Fluor bedeutet und X Wasserstoff oder Fluor, dadurch gekennzeichent, dass ein Cortisonderivat mit den Hydroxygruppen in den Stellungen 16 und 17 unter Bildung eines Ganzacetals mit einem Methylacyloxymethylketon mit nachstehender Formel:in which R, is an alkyl group, and in which P is fluorine and X is hydrogen or fluorine, characterized in that a cortisone derivative with the hydroxyl groups in positions 16 and 17 forms a whole acetal with a methylacyloxymethyl ketone with the following formula: - IL1 - IL 1 in der R-, wenigstens 3 C-Atome und höchstens 5 C-Atome hat, zum Reagieren bringt.in which R has at least 3 C atoms and at most 5 C atoms, for React brings. 2. Verfahren nach Patentanspruch 1, dadurch gekennzeichnet, dass die Reaktion bei niedriger Temperatur erfolgt.2. The method according to claim 1, characterized in that that the reaction takes place at low temperature. 3. Verfahren nach Patentanspruch 1, dadurch gekennzeichnet, dass das verwendete Derivat aus 9«-Pluor-löOf -Hydroxyprednisolon besteht,3. The method according to claim 1, characterized in that that the derivative used from 9 "-Pluor-löOf -Hydroxyprednisolon consists, 4. Verfahren nach Patentanspruch 1, dadurch gekennzeichnet, dass das Derivat aus 6Of, 9Oi,- Difluor-loÄ-Hydroxypredniaolon besteht.4. The method according to claim 1, characterized in that that the derivative of 6Of, 9Oi, - Difluor-loÄ-Hydroxypredniaolon consists. 0 09844717 9 30 09844717 9 3
DE19671618028 1966-01-27 1967-01-05 Process for the preparation of methylacyloxymethyl ketals from prednisolone derivatives with 3 to 5 carbon atoms in the acyl group Pending DE1618028A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1048/66A SE307576B (en) 1966-01-27 1966-01-27

Publications (1)

Publication Number Publication Date
DE1618028A1 true DE1618028A1 (en) 1970-10-29

Family

ID=20257516

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19671618028 Pending DE1618028A1 (en) 1966-01-27 1967-01-05 Process for the preparation of methylacyloxymethyl ketals from prednisolone derivatives with 3 to 5 carbon atoms in the acyl group

Country Status (11)

Country Link
US (1) US3524850A (en)
AT (1) AT269385B (en)
BE (1) BE692983A (en)
CH (1) CH487872A (en)
DE (1) DE1618028A1 (en)
ES (1) ES336470A1 (en)
FR (1) FR6257M (en)
GB (1) GB1120337A (en)
GR (1) GR33327B (en)
NL (1) NL6700465A (en)
SE (1) SE307576B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2278122C1 (en) * 2004-12-27 2006-06-20 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) 9α-FLUORO-16α-HYDROXYPREDNISOLON [3H]-ACETONIDE HIGHLY LABELED WITH TRITIUM
WO2011029547A2 (en) * 2009-09-11 2011-03-17 Chiesi Farmaceutici S.P.A. Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3341526A (en) * 1965-01-12 1967-09-12 Bofors Ab Acyloxyacetals of fluoro-16alpha-hydroxyprednisolones

Also Published As

Publication number Publication date
GB1120337A (en) 1968-07-17
US3524850A (en) 1970-08-18
ES336470A1 (en) 1970-04-01
NL6700465A (en) 1967-07-28
FR6257M (en) 1968-08-19
SE307576B (en) 1969-01-13
BE692983A (en) 1967-07-03
GR33327B (en) 1967-11-23
AT269385B (en) 1969-03-10
CH487872A (en) 1970-03-31

Similar Documents

Publication Publication Date Title
CH635594A5 (en) METHOD FOR PRODUCING NEW GONA 4.9 (10) SERVICES.
DE2318767C3 (en) Triamcinolone derivative, process for its preparation and medicinal product containing it
DE1618028A1 (en) Process for the preparation of methylacyloxymethyl ketals from prednisolone derivatives with 3 to 5 carbon atoms in the acyl group
DE3336292A1 (en) NEW DICHLOR DERIVATIVES OF THE 16 (ALPHA) METHYLPREGNAN SERIES, THEIR PRODUCTION, THEIR USE AS MEDICINAL PRODUCTS AND THE COMPOSITIONS CONTAINING THEM
DE1618993B1 (en) Process for the preparation of 3- (2&#39;-chloroethylthio) -6-formyl steroids
DE2852055C2 (en)
DE1793600A1 (en) Process for making steroid compounds
DE1188079B (en) Process for the preparation of 17alpha, 21-dioxysteroids
CH494218A (en) 3-Oximino-androstenes and gonenes
DE2630270A1 (en) 21-ACETALS AND MIXED 21-ACETALS OF STEROID-21-ALDEHYDE, INTERMEDIATE PRODUCTS AND METHOD FOR MANUFACTURING THE SAME
DE1193941B (en) Process for the preparation of therapeutically effective 16beta-alkyl-9alpha-fluoro-11beta, 17alpha, 21-trioxy-4-pregnen-3, 20-dione-21-acylates or the corresponding 2
DE1618917C3 (en) 6 alpha, 21-difluorosteroids and processes for their production
AT216151B (en) Process for the preparation of deserpidic acid esters
DE1668859C (en) 6 alpha, 9 alpha difluorohydrocortisone or prednisolone 17 valerate
DE1568216C (en) Cardenohd digitoxoside carrying cyclic ethers in position 3,4 and process for their preparation
DE1593204C (en) 19-nor-delta high 4,6 -3,20-diketosteroids, process for their preparation and pharmaceuticals
DE2056512C3 (en)
DE3028255A1 (en) NEW HALOGEN DERIVATIVE FROM THE 16 ALPHA METHYLPREGNAN RANGE, ITS PRODUCTION, ITS USE AS MEDICINAL PRODUCTS AND THE COMPOSITIONS CONTAINING IT
AT249865B (en) Process for the preparation of new pyrazole compounds of the pregnane series
DE1618662C3 (en) 6-substituted 16alpha-methyl-4-pregnen- or 4,6-pregnadien-3betaol-20-one compounds, processes for their production and pharmaceutical preparations containing them
DE1568219C3 (en) Acovenoside A derivatives and processes for their preparation
DE1668859B1 (en) 6alpha, 9alpha-difluorohydrocortisone or prednilon-17-valerate
DE1618993C (en) Process for the preparation of 3- (2-chloroethylthio) -6-formyl steroids
DE977228C (en) Process for the production of new, low-melting esters of steroid hormones
DE1808425C (en) 3 Oxo 17beta hydroxy 17 alpha (but 2 myl&gt; 13 beta C deep 1 to C deep 3 alkyl gona 4,9,11 tnene